Neurocrine Biosciences (NBIX) Tops Q2 EPS by 44c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $161.44 -0.11%
Revenue Growth %: +26.4%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +26.4%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.25, $0.44 better than the analyst estimate of $0.81. Revenue for the quarter came in at $452.7 million versus the consensus estimate of $446.75 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Nike names former Pfizer CFO David Denton as new finance chief
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
